These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Sieger S; Jiang S; Kleinschmidt J; Eskerski H; Schönsiegel F; Altmann A; Mier W; Haberkorn U Cancer Gene Ther; 2004 Jan; 11(1):41-51. PubMed ID: 14681725 [TBL] [Abstract][Full Text] [Related]
4. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers. Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771 [TBL] [Abstract][Full Text] [Related]
5. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Jiang S; Altmann A; Grimm D; Kleinschmidt JA; Schilling T; Germann C; Haberkorn U Cancer Gene Ther; 2001 Jul; 8(7):469-72. PubMed ID: 11498767 [TBL] [Abstract][Full Text] [Related]
6. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481 [TBL] [Abstract][Full Text] [Related]
7. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. Janousková O; Síma P; Kunke D Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310 [TBL] [Abstract][Full Text] [Related]
8. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas. Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Esandi MC; van Someren GD; Vincent AJ; van Bekkum DW; Valerio D; Bout A; Noteboom JL Gene Ther; 1997 Apr; 4(4):280-7. PubMed ID: 9176512 [TBL] [Abstract][Full Text] [Related]
10. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Kanai F; Shiratori Y; Yoshida Y; Wakimoto H; Hamada H; Kanegae Y; Saito I; Nakabayashi H; Tamaoki T; Tanaka T; Lan KH; Kato N; Shiina S; Omata M Hepatology; 1996 Jun; 23(6):1359-68. PubMed ID: 8675152 [TBL] [Abstract][Full Text] [Related]
11. The effect of HSV-tk/GCV on hepatic specific damage driven by murine ALB promoter/enhancer. Zhang Y; Huang SZ; Zeng YT Yi Chuan Xue Bao; 2004 Oct; 31(10):1053-60. PubMed ID: 15552038 [TBL] [Abstract][Full Text] [Related]
12. Suicide gene therapy using keratin 19 enhancer and promoter in malignant mesothelioma cells. Ishiwata N; Inase N; Fujie T; Tamaoka M; Yoshizawa Y Anticancer Res; 2003; 23(2B):1405-9. PubMed ID: 12820402 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Vile R; Miller N; Chernajovsky Y; Hart I Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096 [TBL] [Abstract][Full Text] [Related]
14. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095 [TBL] [Abstract][Full Text] [Related]
16. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Vile RG; Nelson JA; Castleden S; Chong H; Hart IR Cancer Res; 1994 Dec; 54(23):6228-34. PubMed ID: 7954471 [TBL] [Abstract][Full Text] [Related]
17. Combine cancer gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and Herpes simplex thymidine kinase suicide gene. Pastorakova A; Hlubinova K; Jakubikova J; Altaner C Neoplasma; 2006; 53(5):353-62. PubMed ID: 17013529 [TBL] [Abstract][Full Text] [Related]